Renal sympathetic denervation (RDN) has been introduced as a novel approach to treat patients with so-called resistant hypertension.
sponsor-related biases. 19 As indicated by Shun-Shin et al. in a recent editorial, 20 "measurement of a noisy variable by unblinded optimistic staff is a known recipe for calamitous exaggeration". This is illustrated in Figure 1 . It is unfortunate that selection of patients enrolled in Symplicity HTN-2 and evaluation of efficacy were based on office rather than ambulatory blood pressure (ABPM), which is state-ofthe art, 21 particularly in resistant hypertension. 22 ABPM reduces observer bias and measurement error, minimises the white-coat effect and has greater reproducibility, and therefore provides a better estimate of a patient's usual blood pressure and cardiovascular prognosis. 23, 24 Notwithstanding the well-known, major contribution of poor drug adherence to apparently resistant hypertension [13] [14] [15] [25] [26] [27] , drug adherence was not monitored, either at baseline or during follow-up.
This made the study vulnerable to the Hawthorne effect, i.e. patients changing behaviour -in this case starting taking their drugs as prescribed -in response to the intervention and massive attention devoted to them. The lack of blood pressure decrease in the control group also raised concerns. One would indeed suspect that patients in the control group had not taken their medications properly, in order to keep their blood pressure at a higher level that made them eligible for cross-over to RDN group. 28, 29 Finally, placebo effect and regression to the mean must also be taken into account. Noteworthy, the placebo effect is small by using ambulatory blood pressures 21, 30 ; however ambulatory blood pressures remain as sensitive to the Hawthorne effect as office blood pressure.
Despite the major limitations and potential biases of Symplicity HTN-2, a small open study with suboptimal design including only 106 patients followed up for six months, RDN was adopted in hundreds of centres worldwide. Medtronic Inc ® (Minneapolis, Minnesota) paid $800 million to purchase Ardian ® (Mountain View, California), the company that had developed the technology 5 , and more than ten companies developed their own RDN systems, five of which obtained the CE mark. The procedure was quickly reimbursed in Germany, and later on in Switzerland, Sweden and the Netherlands. While RDN remained an investigational procedure in the US, at least 8,000 31 , possibly 15,000 to 20,000 procedures were performed in Europe and in the rest of the world in less than four years, most of them using the Ardian-Medtronic ® catheter. It may be hypothesised that the massive incomes generated by selling the Symplicity catheter to enthusiastic Europeans contributed to the expenses of the Symplicity HTN-3 study 4 , required by the Food and Drug Administration (FDA) before approval of RDN in the US.
In Symplicity HTN-3 4 , blinding of patients through the use of a sham procedure and wider use of ambulatory blood pressure measurement balanced and limited the differential impact of the Hawthorne, white coat, placebo and regression to the mean effects in both treatment arms. This disclosed to the world the true size of blood pressure decrease attributable to RDN, at least in patients meeting the Symplicity criteria; it was less than 3 mmHg systolic based on ambulatory blood pressure monitoring ( Table 1) . Sham-procedure is however not feasible in clinical practice but was required by FDA in the Symplicity Study to overcome all the pitfalls in hypertension research mentioned above in order to investigate whether RDN has a true blood pressure lowering effect and the procedure may be characterised as "evidence based medicine". Taken together with another four prospective and randomised clinical trials published or presented in 2014, discussed below, RDN as of today obviously does not fulfill these criteria and should not be used outside research protocols.
For all aforementioned reasons, and in view of the complexity and multifactorial character of hypertension, the failure of RDN to normalise or substantially reduce blood pressure in all patients with apparently resistant hypertension was a reasonable working hypothesis for us, even before the Medtronic announcement that Symplicity HTN-3 had failed to meet its primary endpoint (http://www.tctmd.com/show. aspx?id=123265 ). We [32] [33] [34] and others 19, 28 had predicted that the true effect of RDN might have been overestimated and may considerably shrink in properly designed studies. 19, 29 In particular, in preliminary analysis of the European Network COordinating research on Renal Denervation (ENCOReD) network, 35 we were struck by the imbalance between the 17.6 mmHg decreases in office blood pressure, vs only 5.9 mmHg for 24-h ambulatory blood pressure. The ENCOReD site in Oslo, with longstanding traditions for randomised research in hypertension 36 , applied a simple and practical way to deal with pitfalls in the recruitment of patients with resistant hypertension. After extensively ruling out secondary hypertension, and improving drug treatment in the run-in phase, patients had to qualify for the RDN protocols by having elevated daytime ambulatory blood pressures after witnessed oral intake of their prescribed blood pressure medication. 33 This was a convenient way to identify the true treatment-resistant hypertensive patients and to exclude patients with white coat hypertension or those non-adherent patients whose blood pressure normalised after witnessed drug intake. Meanwhile a centre in Germany 37 published a small but well documented series of patients whose blood pressure remained unchanged after RDN. We were thus not surprised when the Oslo activity found no change in either office or ambulatory blood pressures following RDN, first in an open series of six patients 33 and later followed by a randomised study, the Oslo-RDN trial. 38 Patients who were randomly assigned to further improvement of drug treatment guided by noninvasive haemodynamic monitoring had normalised blood pressures.
The figure gives an overview of the European Network COordinating research on Renal Denervation (ENCOReD) network with investigational sites in 15 countries. The ENCOReD network is set up to include hundreds of patients in randomised protocols
In contrast, patients exposed to RDN experienced only a small and probably partly placebo-induced fall in office and ambulatory blood pressures (see Table 1 ). The decreases averaged 20 mmHg more for office and 9 mmHg more for ambulatory systolic blood pressure in the haemodynamically guided drug treatment group compared to the RDN group. the defects and inconsistencies in such meta-analysis encountered great delay in getting published. 41 Many never questioned whether RDN should be implemented, but when it should start in an institution.
By all means, the purpose was to disseminate the enthusiasm for RDN from the technically-oriented invasive radiologists and cardiologists who usually had little interest or experience in the treatment of hypertension to the "hypertension establishment." The European Society of Hypertension issued specific guidelines, 42, 43 but maintained reservations that more data was needed, and eventually it had to be proven that RDN would lower morbidity and mortality before being generally accepted in the treatment of true or apparent treatment-resistant hypertension. The key message of Symplicity HTN-3 4 is simple and we should be wise enough to accept it: the true overall benefit of RDN on systolic blood pressure is modest, <3 mmHg, without evidence of a favourable impact on morbidity-mortality so far. The results of three other recent rigorously designed randomised controlled trials, Oslo RDN 38 (see Table 1 ), DENER-HTN 46 , and PRAGUE-15 47 including a smaller number of well-trained operators are in line with those of Symplicity HTN-3 4 , and confirm that the failure of RDN to achieve superiority over medical treatment in the latter cannot be merely explained by inclusion of a 49, 50 that abdominal sympathectomy associated to splanchnicectomy is effective in the treatment of severe hypertension. Finally, many centres report major responses to RDN in a minority of patients. 33, 35, 38 Accordingly, research should go on to find out the minority of patients who are true responders to RDN, and identify predictors of effective RDN. The ENCOReD network (see Figure 2) is set up to include hundreds of patients in randomised protocols, observational studies and registries independent of industry. Some early results 35, 51 from this joint effort have already been published and suggest that it may be worthwhile searching for potential predictors of response to RDN.
As of now, the modest overall benefits and high cost of RDN should be balanced with its potential risks. In particular, more than 20 cases of de novo renal artery stenosis have been reported after RDN, 52 most of them after the announcement that Symplicity HTN-3 failed to meet its primary endpoint. RDN deserves further investigation but is not ready for clinical deployment and its use should be restricted to research protocols. Accordingly, in Germany, the insurances companies which were the first in Europe to reimburse the procedure have terminated their coverage, and even well-known proponents of the technique acknowledge that RDN "should be returned back to the academic arena" 53 before further clinical deployment.
In a substantial proportion of patients, resistant hypertension may reflect resistance to taking medications rather than true treatment resistance. 54 In this perspective, therapeutic drug monitoring may prove an effective strategy, not only for detecting poor drug adherence but also for improving blood pressure control. Indeed, when non-adherent patients are confronted with their low or undetectable drug levels and provided additional counselling to overcome barriers of adherence, blood pressure control improves considerably without intensification of therapy. 55 Along the same lines, a recent analysis based on German data and life statistics showed that therapeutic drug monitoring is a cost-effective health care intervention in patients diagnosed with apparent drug-resistant hypertension, and this finding is valid for a wide range of patients, irrespective of age and sex. 56 Even in truly resistant hypertensive patients with demonstrated drug adherence, blood pressure control may be achieved in a substantial proportion of patients by skilful drug treatment adjustment. 33, 38 While RDN deserves more in depth research, in the present state of knowledge, initiatives aiming at diagnosing and improving poor drug adherence 56, 57 and optimisation of drug treatment 51 may prove much more cost-effective, both at the individual and public health level. n 
